The Natco Pharma stock has outperformed the BSE Health Care Index by a huge margin last year. The company, which manufactures formulations, APIs and offers contract research and manufacturing services, is also a leading player in the oncology therapeutic segment, and derives a considerable portion of its revenues from it. Natco is also among the largest contract manufacturers in India, and has well-known pharma companies such as Ranbaxy and Dr Reddy's as its clients.
The US market (including US retail business) also makes a key segment for Natco. So far, Natco has filed 18 ANDAs, has received approvals for five drug applications and launched three products; three filings enjoy a Para IV certification. It has mitigated the risks of operating in this segment by opting for a partnership model. It has tied with US-based Mylan Inc for Glatiramer Acetate, a generic version of Teva's CopaxoneR, used to treat multiple sclerosis. It has also tied-up with Lupin (Lanthanum Carbonate tablets), Watson Pharma (Revlimid) and Dr Reddy's (for value-added generic oncology drugs). These add a lot of weight to its growth potential. In a first such move, Natco has also sought a voluntary license from Pfizer to make and sell copies of the latter's HIV medicine in India.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.